MXCT PE Ratio & Valuation, Is MXCT Overvalued
MaxCyte Inc (MXCT) is currently considered undervalued, with a fair price estimated between $2.44 and $7.04 compared to its current price of $0.75. Its Price-to-Book ratio is 0.47, significantly lower than its historical averages. However, its P/S ratio of 2.06 is considerably above the industry average, and its Forward Free Cash Flow yield is negative.
MaxCyte (MXCT) price target decreased by 14.88% to 4.90
This article reports that MaxCyte (MXCT)'s price target has been decreased by 14.88%, bringing it down to 4.90. The content provided is minimal, offering only this specific financial update.
MaxCyte (MXCT) price target decreased by 14.88% to 4.90
This article reports that MaxCyte (MXCT) has had its price target decreased by 14.88%, bringing it down to 4.90. The brief update does not provide further details or analysis regarding the adjustment.
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MaxCyte, Inc. announced inducement awards granted to Parmeet Ahuja as he joins the company as Chief Financial Officer. These awards, consisting of stock options and restricted stock units, were issued in accordance with Nasdaq Listing Rule 5635(c)(4). The grants are part of his employment agreement with vesting schedules tied to continuous service.
MaxCyte (MXCT) CEO awarded 600,000 options and 300,000 RSUs
MaxCyte (MXCT) CEO Masoud Maher was granted an equity compensation package including 600,000 stock options and 300,000 restricted stock units (RSUs). The stock options have an exercise price of $0.684 per share and expire in 2036, with vesting tied to continued service. The RSUs also vest over several years, contingent on his employment with the company.
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MaxCyte, Inc. announced inducement awards granted to Parmeet Ahuja upon his appointment as Chief Financial Officer. These awards, consisting of stock options for 375,000 shares and a restricted stock unit award for 187,500 shares, were made under the company's 2026 Inducement Plan. The grants are intended to incentivize Mr. Ahuja's employment and vest over four years, subject to his continuous service.
New MaxCyte CFO gets 562,500-share inducement award under Nasdaq rule
MaxCyte has granted its new Chief Financial Officer, Parmeet Ahuja, inducement awards totaling 562,500 shares, comprising 375,000 stock options and 187,500 restricted stock units (RSUs). These awards, granted under Nasdaq Listing Rule 5635(c)(4), are designed to incentivize Mr. Ahuja and will vest over four years, subject to his continued employment. The stock options have an exercise price matching the closing price of MaxCyte's common stock on March 30, 2026, at $0.676.
MaxCyte (NASDAQ:MXCT) Upgraded by Wall Street Zen to Hold Rating
Wall Street Zen has upgraded MaxCyte (NASDAQ:MXCT) from a "sell" to a "hold" rating, contributing to a consensus "Hold" rating among analysts with a target price of $5.50. Despite beating EPS estimates in its latest quarter, MaxCyte missed revenue expectations and exhibits negative net margin and return on equity. The stock is currently trading significantly below its 200-day moving average and one-year high.
MaxCyte appoints Parmeet Ahuja as CFO, succeeding Douglas Swirsky
MaxCyte has announced the appointment of Parmeet Ahuja as its new Chief Financial Officer, effective March 30, 2026. Ahuja will succeed Douglas Swirsky in the role. Ahuja brings over 20 years of finance leadership experience, including previous roles as VP of Investor Relations and VP of FP&A at Agilent.
MaxCyte, Inc. (MXCT) reports Q4 loss, misses revenue estimates
MaxCyte, Inc. (MXCT) announced its Q4 earnings, reporting a loss per share of $0.21, which was worse than analysts' expectations of a $0.09 loss. The company also missed revenue estimates, reporting $9.74 million against an expected $10.60 million. This performance contrasts with the previous year's Q4 loss of $0.11 per share and higher revenues.
MaxCyte Appoints New Chief Financial Officer Ahuja
MaxCyte has appointed Parmeet Ahuja as its new Chief Financial Officer, effective March 30, 2026. Ahuja brings over two decades of financial experience from Agilent Technologies, signaling MaxCyte's focus on strengthening its financial operations and investor relations. His compensation package includes a $450,000 base salary, a target cash bonus, and substantial equity awards, with the company's stock currently holding a "Sell" recommendation from Spark, TipRanks’ AI Analyst, due to weak financial performance despite a strong cash balance.
New MaxCyte (NASDAQ: MXCT) CFO Parmeet Ahuja joins from Agilent
MaxCyte, Inc. has announced the appointment of Parmeet Ahuja as its new Chief Financial Officer and principal accounting officer, effective March 30, 2026. Ahuja brings over two decades of financial leadership experience from Agilent Technologies. His compensation includes an annual base salary of $450,000, a target cash bonus, and significant equity awards, with a severance agreement also in place.
Vanguard disaggregates holdings; reports 0% stake in MaxCyte (MXCT)
The Vanguard Group has filed an amended Schedule 13G/A report indicating zero beneficial ownership of MaxCyte Inc. common stock. This change, effective January 12, 2026, is due to an internal realignment where certain Vanguard subsidiaries will now report their holdings separately. The filing confirms 0 shares (0%) beneficially owned by The Vanguard Group itself, with no sole or shared voting or dispositive power over MaxCyte stock.
MaxCyte, Inc. (NASDAQ:MXCT) Receives Average Rating of "Hold" from Brokerages
MaxCyte, Inc. (NASDAQ:MXCT) has received an average "Hold" rating from brokerages, based on analyses from five firms. The company's average 12-month price target is set at $5.50. Despite beating EPS estimates, MaxCyte missed revenue expectations and reported negative net margin and return on equity.
MaxCyte Faces Nasdaq Delisting Risk as Share Price Slump Threatens Liquidity and Capital Access
MaxCyte, Inc. (MXCT) is facing a significant risk of Nasdaq delisting due to its share price trading below $1.00 for an extended period. A delisting could severely impact the company's liquidity, reduce its stock's trading volume and market price, and restrict its ability to raise capital. Investors would face wider spreads and lower analyst coverage if the stock moves to an over-the-counter market, further affecting market confidence and MaxCyte's business prospects.
MaxCyte, Inc. (MXCT) reports Q4 loss, misses revenue estimates
MaxCyte, Inc. (MXCT) reported a loss for the fourth quarter, with its adjusted loss per share meeting analyst expectations. However, the company missed revenue estimates for the period. For the full year, MaxCyte expects to see revenue between $38 million and $42 million.
MaxCyte 2025 10‑K: Revenue $33.0M, EPS $(0.42)
MaxCyte reported 2025 revenue of $33.0 million, a 15% decrease year-over-year, and a net loss per share of $(0.42). The company's operating loss was $(51.9) million, mostly flat compared to 2024, and its net loss was $(44.6) million. Despite the revenue decline, MaxCyte expanded its installed instrument base and implemented a workforce reduction to optimize operating expenses and focus on growth areas.
MaxCyte, Inc. (NASDAQ:MXCT) Q4 2025 earnings call transcript
This document is a transcript of the Q4 2025 earnings call for MaxCyte, Inc. (NASDAQ:MXCT). It captures the discussions and financial results presented by the company during the call.
MaxCyte, Inc. (NASDAQ:MXCT) Q4 2025 earnings call transcript
This article is an earnings call transcript for MaxCyte, Inc. (NASDAQ:MXCT) from their Q4 2025 earnings. It likely covers financial results, company updates, and future outlook discussed during the call.
MaxCyte, Inc. (NASDAQ:MXCT) Q4 2025 Earnings Call Transcript
MaxCyte, Inc. (NASDAQ: MXCT) held its Q4 and full-year 2025 earnings call, reporting a challenging year with a 15% decline in total revenue to $33 million, largely due to program consolidation among Strategic Platform License (SPL) customers and inventory management by its largest client. Despite the headwinds and a projected revenue decline for 2026, the company launched its new ExPERT DTX platform, expects significant growth from its SecurDx acquisition, and highlighted the progression of several SPL programs into pivotal studies, including the commercial ramp of CASGEVY. MaxCyte anticipates future growth from new SPLs and increasing complexity in cell therapy, positioning itself for a stronger performance in 2027 and 2028 with a reduced cash burn and a solid balance sheet.
MaxCyte 2025 Financial Results Review
MaxCyte reported a total revenue of $33.0 million for the full year 2025, with a net loss per share of $(0.42). In the fourth quarter of 2025, revenue was $7.3 million and the net loss per share was $(0.09). The company concluded 2025 with $155.6 million in cash and investments, a gross profit of $26.8 million, and a reduced annual cash burn of over $16 million.
MaxCyte Inc (MXCT) Q4 2025 Earnings Call Highlights: Navigating Revenue Declines Amid Strategic ...
MaxCyte Inc (MXCT) reported a 15% decline in total revenue for 2025 and a 22% decrease in core revenue for Q4 2025, driven by customer program consolidations. Despite these challenges, the company launched the ExPERT DTx platform, integrated SeQure DX, and maintains a strong balance sheet with $155.6 million in cash and no debt. MaxCyte anticipates continued revenue challenges in 2026 but expects stabilization and growth in the second half of the year, supported by new Strategic Platform Licenses and early sales of the ExPERT DTx.
MaxCyte, Inc. (MXCT) Announces Fourth Quarter Loss, Falls Short of Revenue Projections
MaxCyte, Inc. (MXCT) reported a fourth-quarter loss of $0.06 per share, which was better than the consensus forecast but still represented a drop in revenue compared to the previous year, falling short of expectations. The company's shares have declined significantly this year, and its future performance will likely depend on management guidance and evolving earnings estimates. MaxCyte currently holds a Zacks Rank #3 (Hold).
MaxCyte, Inc. (MXCT) Announces Fourth Quarter Loss, Falls Short of Revenue Projections
MaxCyte, Inc. (MXCT) reported a quarterly loss of $0.06 per share, surpassing the consensus forecast of a $0.08 loss, but revenue of $7.3 million fell short of expectations by nearly 18%. The company's shares have declined by approximately 51.2% year-to-date, contrasting with the S&P 500's 3.9% drop. The article uses Zacks Rank data to suggest MXCT is likely to perform in line with the market in the near term, with future performance dependent on earnings calls and evolving projections.
MaxCyte, Inc. (MXCT) Reports Q4 Loss, Misses Revenue Estimates
MaxCyte, Inc. (MXCT) reported a Q4 loss of $0.06 per share, outperforming the Zacks Consensus Estimate of a $0.08 loss, but missed revenue estimates with $7.3 million against an expectation of $8.9 million. The company's shares have fallen 51.2% year-to-date, underperforming the S&P 500. The Zacks Rank currently rates MXCT as a #3 (Hold), indicating that the stock is expected to perform in line with the market.
MaxCyte (NASDAQ:MXCT) Issues Earnings Results
MaxCyte (NASDAQ:MXCT) announced its latest earnings, reporting an adjusted EPS of -$0.09, missing the consensus estimate of -$0.08, and revenue of $6.76 million, below the expected $9.16 million. The company recorded significant negative net margins and return on equity. MXCT shares traded down, reflecting its ongoing challenges and a mixed analyst sentiment with an average "Hold" rating but several recent downgrades to "Sell."
MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance
MaxCyte, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025, revealing total revenue of $7.3 million for Q4 2025 and $33.0 million for the full year 2025, both at the top end of preliminary expectations. Despite a 15% decrease in revenue year-over-year due to headwinds from certain Strategic Platform License (SPL) customers, the company reduced its annual cash burn and is focusing on expanding its sales pipeline and new product launches for future growth. MaxCyte provided 2026 revenue guidance of $30-32 million, consisting of $25-27 million in core revenue and approximately $5 million from SPL Program-related revenues.
MaxCyte (NASDAQ: MXCT) 2025 revenue falls and company issues 2026 outlook
MaxCyte (NASDAQ: MXCT) reported a decline in revenue for full-year 2025, falling to $33.0 million from $38.6 million in 2024, alongside a net loss of $44.6 million. Despite strong gross margins, the company issued a cautious outlook for 2026, projecting total revenue of $30–32 million due to "customer headwinds" in its Strategic Platform License (SPL) programs. MaxCyte reaffirmed its solid cash position, expecting to end 2026 with at least $136 million, and emphasized efforts to streamline costs and advance new product launches.
MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer
MaxCyte, Inc. announced the appointment of Parmeet Ahuja as its new Chief Financial Officer, effective March 30, 2026. Mr. Ahuja brings over 20 years of finance leadership experience from Agilent Technologies, where he served as Vice President, Investor Relations. He will succeed Douglas Swirsky and aims to strengthen the company's financial operations and support its strategic growth in cell engineering.
MaxCyte, Inc. Appoints Parmeet Ahuja as Chief Financial Officer, Effective March 30, 2026
MaxCyte, Inc. has announced the appointment of Parmeet Ahuja as its new Chief Financial Officer, effective March 30, 2026. Ahuja will succeed Douglas Swirsky, who is transitioning from the role. Mr. Ahuja brings over 20 years of finance leadership experience, including his most recent role as Vice President, Investor Relations at Agilent Technologies.
MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer
MaxCyte, Inc. announced the appointment of Parmeet Ahuja as its new Chief Financial Officer, effective March 30, 2026. Ahuja brings over two decades of finance leadership experience from Agilent Technologies, where he most recently served as Vice President, Investor Relations. He will succeed Douglas Swirsky and is expected to strengthen MaxCyte's financial operations and support its next phase of growth.
Agilent investor relations veteran Parmeet Ahuja joins MaxCyte as CFO
MaxCyte (Nasdaq: MXCT) has appointed Parmeet Ahuja as its new Chief Financial Officer, effective March 30, 2026, succeeding Douglas Swirsky. Ahuja brings over 20 years of finance leadership experience from Agilent Technologies, including investor relations and financial planning roles. The company expects his expertise to strengthen financial operations, support disciplined execution, and advance its strategic priorities in cell and gene therapy.
MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer
MaxCyte, Inc. (Nasdaq: MXCT) has appointed Parmeet Ahuja as its new Chief Financial Officer, effective March 30, 2026. Mr. Ahuja brings over 20 years of finance leadership experience from Agilent Technologies, where he most recently served as Vice President, Investor Relations. He will succeed Douglas Swirsky and is expected to strengthen MaxCyte's financial operations and support its next phase of growth in the cell and gene therapy industry.
MaxCyte (NASDAQ:MXCT) Rating Lowered to "Sell" at Wall Street Zen
MaxCyte (NASDAQ:MXCT) has been downgraded from a "hold" to a "sell" rating by Wall Street Zen, a sentiment echoed by Weiss Ratings which reaffirmed a "sell (e+)" rating. Despite these downgrades, the street consensus remains an average "Hold" with a $6.00 target price. The stock opened at $0.76, near its 52-week low, and institutional investors own approximately 68.81% of its shares.
MaxCyte (MXCT) Stephens 26th Annual Investment Conference | NASH2024 Summary
MaxCyte (MXCT) presented at the Stephens 26th Annual Investment Conference, highlighting its renewed focus on cell and gene therapy through its non-viral cell engineering platform. The company emphasized its strategic leadership, operational improvements, and market differentiation, especially with its technology being used in the manufacturing of Casgevy. MaxCyte also noted the recovery of the cell and gene therapy industry and increased investment in T cell therapeutics, as well as an expanding focus on autoimmune and solid tumor indications.
MaxCyte receives Nasdaq notice for non-compliance with minimum bid price
MaxCyte, Inc. (NASDAQ:MXCT) has received a notice from Nasdaq for failing to meet the minimum bid price requirement, as its stock closed below $1.00 for 30 consecutive trading days. The company has until September 14, 2026, to regain compliance by ensuring its common stock trades at or above $1.00 for at least 10 consecutive trading days. Failure to comply could lead to delisting, though MaxCyte may be eligible for an extension or has the right to appeal any delisting determination.
Form 8K MaxCyte Inc For: 20 March
This article announces the filing of a Form 8K by MaxCyte Inc on March 20. It includes a general disclaimer about the risks associated with trading financial instruments and cryptocurrencies, emphasizing that the provided market data may not be real-time or accurate. The content also notes that Fusion Media is not liable for losses based on its website's information.
MaxCyte Disclosed Failure to Satisfy a Continued Listing Rule or Standard
MaxCyte (MXCT) received a notice from Nasdaq on March 16, 2026, indicating non-compliance with the minimum $1.00 bid price requirement, having traded below this threshold for 30 consecutive days. The company has 180 days, until September 14, 2026, to regain compliance by achieving a $1.00+ closing bid for at least 10 consecutive trading days. Failure to do so may lead to seeking an additional 180-day period by transferring to the Nasdaq Capital Market.
MaxCyte (NASDAQ: MXCT) faces Nasdaq $1 bid-price deficiency and delisting risk
MaxCyte (NASDAQ: MXCT) has received a notice from Nasdaq stating that its common stock no longer meets the minimum $1.00 bid price requirement for continued listing, as its closing bid price has been below this threshold for 30 consecutive trading days. The company has 180 calendar days, until September 14, 2026, to regain compliance. Failure to do so could lead to a possible transfer to the Nasdaq Capital Market or eventual delisting.
MaxCyte Faces Nasdaq Noncompliance Over Minimum Bid Price
MaxCyte (MXCT) received a Nasdaq notice on March 16, 2026, for failing to meet the $1.00 minimum bid price requirement for 30 consecutive trading days. The company has until September 14, 2026, to regain compliance, with potential for delisting and investor uncertainty if it fails. An analyst has rated MXCT as a Buy with a $9.00 price target, while TipRanks' AI analyst, Spark, rates it Neutral, citing financial challenges alongside strong shareholder support and strategic plans.
MaxCyte (MXCT) CFO covers RSU tax withholding through automatic share sale
MaxCyte's CFO, Douglas J. Swirsky, sold 10,142 shares of common stock at a weighted average price of $0.815 per share. This sale was an automatic, non-discretionary transaction to cover tax withholding obligations upon the vesting of previously granted Restricted Stock Units (RSUs). Following the transaction, Swirsky directly holds 151,669 shares of MaxCyte common stock.
Mirabella Financial Services LLP Purchases 1,600,000 Shares of MaxCyte, Inc. $MXCT
Mirabella Financial Services LLP increased its stake in MaxCyte, Inc. (NASDAQ:MXCT) by 24.2% in Q3, purchasing 1,600,000 shares and now owning 8,200,000 shares, making it their 17th largest holding. MaxCyte, a clinical-stage cell therapy company, is currently trading at $0.81 with a market cap of $86.51 million, reflecting a volatile stock with institutional investors holding approximately 68.8% of outstanding shares. Analysts have a consensus "Hold" rating with a target price of $6.00, despite the stock's recent performance.
MaxCyte (MXCT) Projected to Post Earnings on Tuesday
MaxCyte (MXCT) is expected to announce its Q4 2025 earnings after the market closes on Tuesday, March 24th, with analysts forecasting an EPS of ($0.08) and revenue of $9.158 million. The stock currently trades at $0.81 with a market cap of $86.51 million and institutional ownership of 68.81%. Wall Street has a consensus "Hold" rating with an average price target of $6.00, despite recent mixed analyst actions.
MaxCyte (NASDAQ:MXCT) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen has upgraded MaxCyte (NASDAQ:MXCT) from a "sell" to a "hold" rating, while Weiss Ratings reissued a "sell (e+)." The company currently has a consensus "Hold" rating from analysts with an average price target of $6.00 and a market capitalization of $87.45 million. Institutional investors own approximately 68.81% of the stock, with several firms recently increasing their stakes.
MaxCyte unveils new 96-well electroporation platform to accelerate discovery
MaxCyte has launched ExPERT DTx, a new 96-well electroporation platform designed to accelerate research and drug discovery. This high-throughput system can process up to 96 samples in three minutes, enabling flexible experimentation and simplifying scale-up to cGMP manufacturing. The platform's user-friendly software and ability to process different cell and cargo combinations maximize efficiency and provide valuable insights for cell and gene therapy development and protein production.
MaxCyte (NASDAQ:MXCT) Stock Rating Lowered by Wall Street Zen
Wall Street Zen has downgraded MaxCyte (NASDAQ:MXCT) from a "hold" to a "sell" rating, while Weiss Ratings reiterated a "sell (e+)." Despite this, MarketBeat's consensus rating for MaxCyte remains "Hold" with a target price of $7.00. MaxCyte shares fell approximately 6.7%, opening at $0.78, and institutional investors collectively own 68.81% of the company's stock.
Free cash flow per share of MaxCyte, Inc. – FWB:MYE0
This article provides financial information for MaxCyte, Inc., specifically focusing on its free cash flow per share. The data is available on TradingView, an investment analysis platform, for the company's Frankfurt Stock Exchange listing (FWB:MYE0). The platform offers various analytical tools and market data for investors.
MaxCyte, Inc. (NASDAQ:MXCT) Receives Average Rating of "Hold" from Analysts
MaxCyte, Inc. (NASDAQ:MXCT) has received an average "Hold" rating from analysts, with a consensus 1-year price target of $7.00. The stock is currently trading significantly below this target at approximately $0.81, with a market capitalization of $86.5 million and a negative P/E ratio. Institutional investors hold a majority stake, and the company specializes in cell therapy platform technology.
MaxCyte (MXCT) Launches ExPERT DTx Platform to Accelerate High-Throughput Drug Discovery
MaxCyte Inc. (MXCT) recently launched its ExPERT DTx platform, a high-throughput 96-well electroporation system aimed at accelerating drug discovery and research. This platform allows for rapid transfection of cells with minimal stress, streamlining lab workflows and enabling seamless transition from early-stage discovery to large-scale cGMP-compliant manufacturing. The company believes this technology positions MXCT as a strong investment, although it also suggests looking into AI stocks for potentially greater upside.
MaxCyte (MXCT) Launches ExPERT DTx Platform to Accelerate High-Throughput Drug Discovery
MaxCyte (MXCT) has launched its ExPERT DTx platform, a high-throughput 96-well electroporation system aimed at speeding up drug discovery. This modular system enables transfection of various cell types with minimal stress, streamlining lab workflows and allowing seamless scaling to cGMP-compliant manufacturing. The platform also includes a specialized software suite, the DTx Designer, to enhance laboratory efficiency and instrument uptime.
